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During our ongoing research on fungal strains from unexplored sources, the reinvestigation of 
the CHCl3−MeOH extract of the marine-facultative Aspergillus sp. MEXU 27854 yielded a 
new N-methyl cyclic pentapeptide (1) along with known butyrolactone II and PF1233 A. In 
addition, from the marine-facultative Gymnoascus hyalinosporus MEXU 29901, a new 
alternariol glucoside, 10-O-[β-d-(4-methoxyl-glucopyranosyl)]-4-O-methylalternariol (2) and 
known alternariol 4-O-methyl ether, alternariol and beauvericin, were isolated. The structures 
of 1 and 2 were established by detailed spectroscopic data, and their absolute configuration was 
ascertained by Marfey’s analysis and HRESIMS-MS/MS data for 1, and by chemical 








Fungi are considered one of the most diverse group of organisms with over 120,000 currently 
recognized species and an estimated of 2.2 to 3.8 million worldwide [1]. Mycodiversity of 
Mexico has been poorly studied, and some authors have proposed the existence of around 
200,000 fungal species, but less than 10,000 remain taxonomically described [2], and even fewer 
investigated for their secondary metabolites chemistry [3]. Thus, fungal species isolated from 
unexplored sources in Mexico represent an important source of new chemical diversity and 
bioactive compounds. 
 
During our ongoing research on fungal strains from different regions of Mexico, a sample of 
sand from the intertidal zone of Caleta Bay in Acapulco, Guerrero, Mexico, was collected. From 
this, several fungal strains were isolated, and the chemical study of a marine-facultative 
Aspergillus sp. MEXU 27854 yielded a series of new dioxomorpholines [4]. In this work, we 
describe the reinvestigation of this strain and include the characterization of a new N-methyl 
cyclic pentapeptide, caletasin (1), the known butyrolactone II and the dioxomorpholine PF1233 
A. Furthermore, from another marine-facultative fungus isolated from the same sample of 
sand, Gymnoascus hyalinosporus MEXU 29901, a new alternariol glucoside (2) and the known 
alternariol 4-O-methyl ether, alternariol, and beauvericin were obtained. It is interesting that the 
genus Gymnoascus is greatly understudied despite its ubiquitous distribution. Gymnoascus 
dankaliensis, G. aurantiaca, G. reessii, and G. cetosus are the only species studied for their 
secondary metabolites production [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15]. As such, 
this is the first chemical study of G. hyalinosporus. 
 
Solid-phase cultures of Aspergillus sp. MEXU 27854 and G. hyalinosporus MEXU 29,901 (Figs. 
S1 and S2) were extracted with CHCl3−MeOH (1:1), and the resulting dry extracts were 
partitioned between n-hexane and CH3CN−MeOH (1:1). Extensive chromatographic 
fractionation and purification of the defatted extracts using preparative RP-HPLC resulted in the 
isolation and purification of new compounds 1 and 2 along with several known metabolites (Fig. 
1), butyrolactone II, PF 1233A, alternariol 4-O-methyl ether, alternariol, and beauvericin, whose 
identity was corroborated by comparison with reported data (Table S1 and Figs. S3–
S8) [16], [17], [18], [19], [20]. 
 
 
Figure 1. Structures of compounds 1 and 2. 
 
Compound 1 [21] was obtained as an orange powder. Its molecular formula was deduced as 
C35H47N5O6 based on the molecular ion peak at m/z 634.3596 [M + H]+ in the HRESIMS (Fig. 
S8), establishing an index of hydrogen deficiency (IHD) of 15. A detailed analysis of the 1D and 
2D NMR spectral data (Table 1 and Figs. S9–S12) revealed that this compound has a peptide 
structure, with a profile similar to that of cotteslosin B [22]. Some key differences between 1 and 
cotteslosin B are the presence of one, instead of two, phenolic hydroxy group at δH 9.02 (1H, s, 
16-OH); a disubstituted ring system represented by a double doublets at δH 6.54 (2H, 
d, J = 8.4 Hz, H-15 and H-17) and 6.65 (2H, d, J = 8.4 Hz, H-14 and H-18) from the aromatic 
protons of a Tyr residue (Fig. S13); and 10 protons of a Leu residue at δH 4.62 (1H, m, H-30), 
1.79 (1H, m, H2a-31), 1.29 (1H, m, H2b-31), 1.49 (1H, m, H-32), 0.89 (3H, d, J = 5.1 Hz, H3-33), 
and 0.87 (3H, d, J = 5.1 Hz, H3-33). 
 
Table 1. NMR data for compound 1 in DMSO-d6 (400 and 100 MHz for 1H and 13C, 
respectively). 
position δC δH, mult. (J in Hz) COSY TOCSY HMBC (H → C) 
N-Me-l-Phe 
1 167.9 
    
2 61.3 4.26, dd (11.4, 3.3) 3 3a, 3b 1, 2-NMe, 3, 10 
3a 33.9 3.26, dd (14.3, 3.3) 2 2, 3b 2, 4, 5/9 
3b 
 
2.78, dd (14.3, 11.5) 
 
2, 3a 2, 4, 5/9 
4 137.2 
    
5/9 128.9 7.09, m 6/8 6/8 3, 6/8, 7 
6/8 128.4 7.19, m 5/9, 7 5/9 4, 5/9, 7 
7 126.6 7.17, m 5/9 
 
5/9, 6/8 





    
11 49.2 3.99, ddd (8.7, 8.2, 5.3) 11-NH, 12 11-NH, 12 10, 12, 19 
12 36.9 a 2.64, dd (14.0, 8.2) 11 11, 11-NH, 12 10, 11, 13, 14/18   
b 2.28, dd (14.0, 5.3) 
   
13 127.4 
    
14/18 129.7 6.50, s 15/17 15/17 12, 13, 15/17, 16 
15/17 114.6 6.50, s 14/18 14/18 13, 14/18, 16 
16 155.3 
    
11-NH 
 








    
20 61.0 3.86, t (9.7) 20-NH, 21 20-NH, 21, 22, 23 19, 21, 22, 23, 24 
21 30.5 1.66, m 20, 22, 23 20, 20-NH, 22, 23 20, 22, 23 
22 19.14 0.78, d (6.6) 21 20, 20-NH, 21, 22 20, 21, 23 
23 19.12 0.65, d (6.6) 21 20, 20-NH, 21, 22 20, 21, 22 
20-NH 
 
7.00, d (9.7) 20 20, 21, 22, 23 20, 24 
l-Pro 
24 170.6 
    
25 61.0 4.39, dd (8.1, 0.8) 26 26, 27, 28 24, 26, 27, 29 
26 31.5 a 2.16, m 25, 27 25, 26, 27, 28 24, 25, 27, 28   
b 1.99, m 
   
27 21.4 a 1.90, m 26, 28 25, 26, 27, 28 25, 26, 28   
b 1.66, m 
   
28 46.3 a 3.61, m 27 25, 26, 27, 28 26, 27   
b 3.38, m 
   
l-Leu 
29 169.3 
    
30 49.1 4.62, m 30-NH, 31 30-NH, 31, 32, 33, 34, 1, 29, 31 
31 41.7 a 1.79, m 30, 32 30, 30-NH, 31, 32, 33, 34 29, 30, 33, 34   
b 1.29, m 
   
32 24.4 1.49, m 31, 33, 34 30, 30-NH, 31, 33, 34 30, 31, 33, 34 
33 22.8 0.89, d (5.1) 32 30, 30-NH, 31, 32, 34 31, 34 
position δC δH, mult. (J in Hz) COSY TOCSY HMBC (H → C) 
34 22.5 0.87, d (5.1) 32 30, 30-NH, 31, 32, 33 31, 33 
30-NH 
 
7.05, d (8.4) 30 30, 31, 32, 33, 34 1, 29, 30 
 
The combined 2D NMR data (Fig. 2) and MS/MS analysis (Fig. S14) allowed the identity and 
connection sequence of the residues. To meet the IHD of 15, 1 must be a cyclic compound; thus, 
the preliminary structure was established as cyclo-(Tyr-N-Me-Phe-Leu-Pro-Val). It is worth 
noting that TOCSY spectrum (Fig. 2C) was particularly helpful to differentiate each spin system 
in 1. Furthermore, the MS/MS analysis (Figs. 3 and S14) revealed fragmentation patterns 
generated from ion fragments m/z 521.2737 [M − Leu + H]+ and m/z 471.2950 [M − Tyr + H]+, 
which are in agreement with the proposed structure. Moreover, this fragmentation suggests two 
main cleavage sites within the peptide (Val/Tyr and Pro/Leu), further confirming the connection 
of the peptide. 
 
Figure 2. Key (A) COSY (bold lines), HMBC (→), and (B) NOESY (↔) correlations observed 




Figure 3. HRESIMS-MS/MS mass fragmentation patterns using Higher-Energy Collisional 
Dissociation (20 mV) of cyclic peptide 1 showing key amino acid losses. 
 
The relative configuration of 1 was determined with the analysis of the correlations in NOESY 
spectrum (Figs. 2B and S12); then, a Marfey’s analysis was performed to assess the absolute 
configuration for each residue (Fig. S15) [23], [24]. In this analysis (Fig. S15), it was impossible 
to achieve full separation of all the amino acids present in the mixture of the derivatized 
standards under any of the experimental conditions evaluated, particularly between l-Leu and d-
Val. To overcome this issue, the HRESIMS data was used: by comparing the mass profiles and 
mass values for each amino acid, it was possible to confirm the presence of l-Leu in the 
hydrolysis product of 1 (Fig. S16). This allowed to establish the final structure of 1 as cyclo-(l-
Tyr-N-Me-l-Phe-l-Leu-l-Pro-l-Val) and was given the trivial name of caletasin. 
 
Compound 2 [25] was obtained as a white amorphous powder and based on the HRESIMS 
analysis, had a molecular formula of C22H25O10 (IHD = 11) (Fig. S8). Its HPLC-UV profile (Fig. 
S17) was very similar to those of the dibenzopyranones alternariol and alternariol 4-O-methyl 
ether, and its NMR data (Table 2 and Figs. S17–S21) suggested a similar backbone to that of 
alternariol 4-O-methyl ether, with the addition of a 4-O-methyl-d-glucopyranose in position 
10 [18], [26], [27]. The later was evidenced by a methylated hexose unit corresponding signals in 
the spectrum: one signal at δC 102.0 in the anomeric region [28]; four signals at δC 80.8, 78.5, 
78.1, 75.4 in the sugar region corresponding to oxygenated carbons; and one signal at δC 61.1 
corresponding to a methoxy group (Fig. S18) [18], [26], [27]. The site of methylation within the 
sugar residue was deduced from the HMBC correlation between H-4′ (δH 3.93, dd, J = 9.4, 
9.0 Hz) and CH3O-4′ (δC 61.1) (Figs. 4 and S19). Additionally, the COSY spectrum provided 
evidence of the sugar assembly, and the coupling constants of protons H-1′ (δH 5.70, 
d, J = 7.8 Hz), H-2′ (δH 4.32, dd, J = 9.0, 7.8 Hz), H-3′ (δH 4.41, t, J = 9.0 Hz), and H-4′, along 
with the NOESY between H-1′ and H-3′, H-3′ and H-5′, and H-2′ and H-4′ defined the relative 
orientation of the hydroxy groups (Figs. 4, S20 and S21). Furthermore, the position of 
glycosylation was determined by the HMBC correlation between the anomeric proton H-1′ and 
C-10 (δC 159.1) of the aglycone portion (Fig. 4). Finally, the D configuration of β-D-4′-
methoxyl-glucopyranosyl residue was established by comparison of the specific rotations of 
aqueous soluble acid hydrolysate product (αD25 + 25, c 0.08, MeOH) with that of 4-O-methyl-d-
glucopyranose (αD25 + 80, c 1.30, MeOH) [29], and the 1H NMR spectrum of the aglycone, 
which was identical to that of 4-O-methyl-alternariol (Fig. S22) [18], [26]. 
 
From all the isolated compounds, only alternariol and beauvericin showed antimicrobial activity 
against B. subtilis (MIC = 40 and 2.5 μg/mL, respectively; positive control, vancomycin, 
MIC = 10 μg/mL) and S. aureus (MIC = 20 and 10 μg/mL, respectively; positive control, 
ampicillin, MIC = 1.25 μg/mL) (Supplementary data). Additionally, compounds 1 and 2 were 
inactive (IC50 less than 25 μM) when tested against MDA-MB-435, MDA-MB-231, and 
OVCAR3 cells lines (Table S2). Finally, none of the tested compounds exhibited inhibitory 
activity against seed germination and radicle growth of Amaranthus 
hypochondriacus (Supplementary data). 
 
Table 2. NMR for compound 2 in pyridine-d5 (500 and 125 for 1H and 13C, respectively). 
position δC, type δH, mult. (J in Hz) 
1 100.3 C 
 
2 166.0 C 
 
3 100.4 CH 6.82, d (2.2) 
4 167.2 C 
 
5 105.3 CH 7.29, d (2.2) 
6 139.2 C 
 
7 112.6 C 
 
8 138.5 C 
 
9 119.1 CH 7.07, d (2.6) 
10 159.1 C 
 
11 103.8 CH 7.25, d (2.7) 
12 153.7 C 
 
13 166.0 C 
 
1′ 102.0 CH 5.70, d (7.8) 
2′ 75.4 CH 4.32, dd (9.0, 7.8) 
3′ 78.5 CH 4.41, t (9.0) 
4′ 80.8 CH 3.93, dd (9.4, 9.0) 
5′ 78.1 CH 4.02, m 
6′ 62.1 CH2 4.36, dd (12.3, 2.0) 
4.24, dd (12.3, 4.7) 
CH3O-4 56.2 CH3 3.81, s 
CH3O-4′ 61.1 CH3 3.90, s 
CH3-8 25.8 CH3 2.66, s 
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